Lazard Asset Management
PRCT icon

Lazard Asset Management’s Procept Biorobotics PRCT Stock Holding History

Lazard Asset Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$843K Buy
37,319
+9,058
+32% +$227K ﹤0.01% 1270
2026
Q1 		$707K Buy
+28,261
New +$796K ﹤0.01% 1271
2025
Q3 		– Sell
-1,703
Closed -$98K – 2213
2025
Q2 		$98K Buy
1,703
+810
+91% +$45.8K ﹤0.01% 1873
2025
Q1 		$52K Buy
+893
New +$61K ﹤0.01% 1987

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lazard Asset Management's PRCT Position: Q2 2026 in Review

Lazard Asset Management increased its Procept Biorobotics (PRCT) stake by 32% in Q2 2026, buying an estimated $227K and bringing the position to 37,319 shares worth $843K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.

Lazard Asset Management first reported a position in PRCT in Q1 2025 and has held it in 4 quarters since. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Lazard Asset Management held 37,319 shares of Procept Biorobotics worth $843K as of Q2 2026.
  • Lazard Asset Management bought 9,058 Procept Biorobotics shares in Q2 2026, an estimated $227K.
  • Procept Biorobotics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1270 holding.
  • Lazard Asset Management first reported a position in Procept Biorobotics in Q1 2025 and has held it in 4 quarters since.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.